利拉鲁肽对2型糖尿病合并非酒精性脂肪肝的疗效  

Effect of liraglutide on type 2 diabetes with non-alcoholic fatty liver

作　　者：张妍[1] 古东海[1] 王新文 柯晓燕[1] 苏锦茜 李洁凌[1] 陈宇锋[1] ZHANG Yan;GU Donghai;WANG Xinwen;KE Xiaoyan;SU Jinxi;LI Jieling;CHEN Yufeng(The People＇s Hospital of Maoming City,Maoming 525000,Chin)

机构地区：[1]广东省茂名市人民医院,广东茂名525000

出　　处：《中国医药科学》2018年第14期30-32,共3页China Medicine And Pharmacy

基　　金：广东省茂名市科技计划项目(2015020)

摘　　要：目的研究分析2型糖尿病合并非酒精性脂肪肝患者应用利拉鲁肽治疗的临床效果。方法随机选取前来我院就诊的2型糖尿病合并非酒精性脂肪肝患者94例,按照随机数字表法将所有患者分成研究组和对照组,两组患者临床治疗中分别应用利拉鲁肽和注射用胰岛素治疗6个月,对比监测患者治疗前及治疗6个月后不同组别患者各生理指标、肝功能各指标、血糖血脂水平以及肝脏1HMRS扫描图像等。结果研究组患者体重、体重指数、腰围均明显低于对照组;研究组患者血糖血脂水平指标中空腹血糖水平(FBG)、餐后2h血糖水平(2h PG)、糖化血红蛋白(HbAlC)、甘油三酯(TG)、总胆固醇(TC)均明显低于对照组;研究组患者肝功能指标中谷丙转氨酶(ALT)和谷草转氨酶(AST)指标均明显低于对照组,上述指标组间比较差异有统计学意义(P<0.05)。结论 2型糖尿病合并非酒精性脂肪肝患者应用利拉鲁肽治疗,能够有效改善患者临床表现、血糖血脂水平及肝功能等,促进患者身体恢复,提高临床疗效,临床应用价值突出。Objective To study and analyze the clinical effects of liraglutide in patients with type 2 diabetes mellitus combined with nonalcoholic fatty liver disease. Methods Ninety-four patients with type 2 diabetes and nonalcoholic fatty liver who treated in our hospital were randomly selected, all patients were divided into study group and control group according to the principle of random number table. The study group was treated with insulin, and the control group was treated with insulin, the course of treatment was 6 months. Before and 6 months after treatment, the physiological parameters, liver function indicators, blood glucose and lipid levels, and liver 1HMRS scan images were measured in two groups. Results The weight, body mass index, and waist circumference of the study group were significantly lower than those of the control group; The fasting blood glucose level（FBG）, 2 hours postprandial blood glucose level（2hPG）, glycated hemoglobin（HbAlC）, triglyceride glycerin（TG） and total cholesterol（TC） in the blood glucose and lipid levels of the study group were significantly lower than those in the control group. The glutamic-pyruvic transaminase（ALT） and glutamic-oxaloacetic transaminase（AST） indexes in the liver function index of the study group were significantly lower than those of the control group. The above-mentioned index groups were significantly different（P 〈0.05）. Conclusion The use of liraglutide in patients with type 2 diabetes mellitus combined with nonalcoholic fatty liver can effectively improve the clinical performance, blood glucose and lipid levels, liver function, etc., and promote the recovery of patients and improve clinical efficacy. The clinical application value is outstanding.

关 键 词：2型糖尿病 胰岛素 非酒精性脂肪肝 利拉鲁肽 

分 类 号：R575.5[医药卫生—消化系统] R587.1[医药卫生—内科学]